Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
HIV Infections: early-phase trial registry
56 of 615 indexed HIV Infections trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #7 of 28,963 conditions by registered trial count.
615 US clinical trials · 56 currently recruiting · #7 of 28,963 conditions by registered trial count
HIV Infections: 615 US clinical trials tracked, 56 recruiting.
HIV Infections is the subject of 615 registered US clinical trials on ClinicalTrials.gov, 56 of them currently open to new participants. 92 are in Phase 3-4 (later-stage) and 266 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Allergy and Infectious Diseases (NIAID), running 195 of these trials.
Open enrollment, early-phase tilt
HIV Infections has 615 registered US clinical trials, 56 of them open to new participants right now, about 9% of the total.
- 56
- recruiting participants now
- 9%
- of trials open to enrollment
- 92
- in Phase 3-4 (later-stage)
- 195
- top sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Corpus placement: #7 of 28,963 conditions by registered trial count on ClinicalTrials.gov-derived indexes. Registry reference only, not medical advice.
Key findings
What ClinicalTrials.gov does not surface for HIV Infections on its own pages , computed from the registry mirror as of 2026-07-11. Each line carries its own denominator so it can be quoted as it stands.
-
HIV Infections is recruiting below its size-band peers.
56 of 615 indexed trials (9.1%) are open to enrollment, against a 37.2% average across 135 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates HIV Infections research.
National Institute of Allergy and Infectious Diseases (NIAID) accounts for 195 of 615 trials (31.7%). 173 distinct sponsors appear on at least one study for this condition label.
-
Typical HIV Infections enrolment sits around 100 participants.
Median target enrolment is 100 among the 543 trials that report a genuine target (sentinel values excluded). 267 of those (49.2%) plan for fewer than 100 participants.
-
HIV Infections research is mostly interventional.
549 interventional and 66 observational studies make up this index (89.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
615 total, page 4 of 13
A Comparison of Two Anti-HIV Treatment Plans
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00005915
A Study to Evaluate the Effects of Giving Proleukin (rIL-2) to HIV-Positive Patients With CD4 Counts Greater Than 300 Cells/mm3
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000949
A Study of Physical and Metabolic Abnormalities in HIV Infected and Uninfected Children and Youth
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00069004
BRAVO: Background Regimen of Raltegravir on Virologic Outcome
Community Research Initiative of New England
NCT00751530
Treatment Success and Failure in HIV-Infected Subjects Receiving Indinavir in Combination With Nucleoside Analogs: A Rollover Study for ACTG 320
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000885
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients
Gilead Sciences
NCT01475838
A Multicenter, Double Blind, Comparative Study of Zidovudine Alone Versus Zidovudine and Acyclovir as Treatment for HIV-Infected Patients With CD4+ Counts Less Than 200 Cells/mm3
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000712
A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal Meningitis
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000639
A Study of the Safety and Effectiveness of Hydroxyurea in Patients on Potent Antiretroviral Therapy and Who Have Less Than 200 Copies/ml of HIV RNA in Their Blood
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000916
Observational Study of Treated and Untreated Acute and Early HIV-1 Infection
Rockefeller University
NCT00219934
A Study on the Safety and Effectiveness of Adefovir Dipivoxil in Combination With Anti-HIV Therapy (HAART) in HIV-Positive Patients
Gilead Sciences
NCT00002426
Reducing HIV Risk Among Episodic Substance Using Men Who Have Sex With Men (SUMSM)
San Francisco Department of Public Health
NCT01279044
Safety of and Immune Response to a Meningitis Vaccine in HIV-Infected Children and Youth
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00459316
A Phase IIIB Open-Label, Comparative Study to Evaluate Saquinavir Soft Gel Capsule (SGC) Treatment in Combination With Other Antiretrovirals in HIV-1 Infected Antiretroviral-Naive Patients
Hoffmann-La Roche
NCT00002178
Medications for Chronic HIV: Education and Collaboration
Boston University
NCT01038076
Gradual Initiation of Sulfamethoxazole/Trimethoprim as Primary Pneumocystis Carinii Pneumonia Prophylaxis
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000816
CSP #512 - Options in Management With Anti-Retrovirals
US Department of Veterans Affairs
NCT00050089
Effectiveness of a Telephone-Delivered Behavioral Treatment to Improve the Quality of Life of Older Adults With HIV
Ohio University
NCT00365690
Using Drug Levels in the Blood to Guide Therapy in HIV Infected Patients Taking a Protease Inhibitor
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00041769
Detection of Human Immunodeficiency Virus Type 1 (HIV-1) in Vaginocervical Secretions: Correlation With Clinical Status, Virologic and Immunologic Parameters, and the Presence of Other Infections
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000858
Spirituality and Will to Live in Patients With HIV/AIDS
National Center for Complementary and Integrative Health (NCCIH)
NCT00122902
Managing Medications
University of Pittsburgh
NCT00222716
Changing to Nonprotease Inhibitor Treatment to Improve Side Effects
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00021463
Evaluation of Many Men, Many Voices, An STD/HIV Prevention Intervention for Black MSM
Centers for Disease Control and Prevention
NCT00137631
GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 Infection
Hoffmann-La Roche
NCT00105079
Safety and Immune Response Study of the Vaccine ALVAC vCP1452 Alone or in Combination With AIDSVAX B/B
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00007332
Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients
Boehringer Ingelheim
NCT00056641
Effects of MAC Preventive Therapy on Disease-Causing Bacteria in HIV-Infected Patients: A Substudy of CPCRA 048
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000933
A Controlled Comparative Trial of Sulfamethoxazole-Trimethoprim Versus Aerosolized Pentamidine for Secondary Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients Receiving Azidothymidine (AZT)
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000727
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00604175
Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Gilead Sciences
NCT01440569
Evaluation of the Healthy Love Workshop, an HIV Prevention Intervention for African American Women
Centers for Disease Control and Prevention
NCT00362375
Comparison of Ro 31-8959 Plus Zidovudine (AZT) Versus AZT Plus Zalcitabine (ddC) Versus Ro 31-8959 Plus AZT Plus ddC
Hoffmann-La Roche
NCT00001040
A Study of Dideoxyinosine (ddI) in HIV-Infected Children Who Have Not Had Success With Zidovudine or Who Cannot Take Zidovudine
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000963
A Study to Compare Two Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Previously Received Anti-HIV Treatment
Abbott
NCT00004581
A Compassionate Use Study of Tenofovir Disoproxil Fumarate as Treatment for HIV Infection
Gilead Sciences
NCT00002453
Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00013871
Metabolic Abnormalities in HIV Infected and Uninfected Young Women
University of North Carolina, Chapel Hill
NCT00067587
Comparison of Three Anti-HIV Drug Combinations in HIV-Infected Patients With No Symptoms of the Disease
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00001045
Pre-HIV Test Counseling Intervention to Reduce HIV Infection Risk Behavior in Men Who Are Not HIV Infected
University of California, San Francisco
NCT00218699
Virologic and Immunologic Activity of Continued Lamivudine (3TC) vs Delavirdine (DLV) in Combination With Indinavir (IDV) and Zidovudine (ZDV) or Stavudine (d4T) in 3TC-Experienced Subjects
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000882
Effects on the Immune System of Anti-HIV Drugs in Patients Recently Infected With HIV
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00001119
When to Start Anti-HIV Drugs in Patients With Opportunistic Infections
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00055120
Project ICARE: Intervening for Community Awareness, Respect, & Empowerment
Centers for Disease Control and Prevention
NCT00712088
Pneumococcal Conjugate Vaccination in HIV in Comparison to Polysaccharide Vaccine Boosting
Henry M. Jackson Foundation for the Advancement of Military Medicine
NCT00622843
Effect of Intermittent Aldesleukin Treatment With or Without Anti-HIV Drugs in HIV Infected People
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00110812
Subclinical Atherosclerosis in HIV-infected Patients
Massachusetts General Hospital
NCT00455793
A Randomized Trial to Evaluate the Safety and Efficacy of Combination Therapy With Retrovir ( AZT ) and HIVID ( ddC ) Versus Retrovir, HIVID, and Wellferon ( Interferon Alfa-n1 ) for the Treatment of HIV Infection
Glaxo Wellcome
NCT00002086
Study Switching HIV-1 Infected Patients With an Undetectable Viral Load on a First Protease Inhibitor-Based Regimen to an Efavirenz-Based Regimen
Bristol-Myers Squibb
NCT00135382
A Study to Evaluate the Impact of Stopping Treatment for the Prevention of Pneumonia in HIV-Positive Patients Receiving Anti-HIV Drugs Who Have Increased CD4 Cell Counts
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00000908
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 157 |
| Phase 2 | 109 |
| Phase 3 | 69 |
| Phase 4 | 23 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
What is open for HIV Infections right now
56 recruiting of 615 indexed (9% open).
Phase mix: 92 late (III/IV) vs 266 early (I/II) (early-phase heavy).
Top sponsor: National Institute of Allergy and Infectious Diseases (NIAID) (195 trials), 9 others listed. 50 shown below, recruiting first. #7 of 28,963 conditions by registered trial count.
How open-enrollment share is computed
Open share is recruiting_count divided by trial_count for this condition label in the public registry export. Status can change between pulls; treat the figure as a snapshot of research attention, not treatment availability.
Frequently Asked Questions
How many clinical trials are there for HIV Infections?
PlainTrial tracks 615 US clinical trials for HIV Infections, of which 56 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for HIV Infections?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.